The 4 most recent market catalysts affecting $HRTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 75
Heron Therapeutics Reports Third Quarter 2026 Financial Results
Heron Therapeutics announced its Q3 2026 financial results, revealing a decrease in total net revenue compared to the same period last year. This revenue decline is a significant c…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 75
Heron Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
This headline represents a significant corporate catalyst for Heron Therapeutics (HRTX). The worse-than-expected Q2 financial results directly impact the company's valuation and in…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 95
Heron Therapeutics Q2 EPS $(0.03) Misses $(0.01) Estimate, Sales $37.666M Miss $42.200M Estimate
Heron Therapeutics (HRTX) reported a Q2 EPS of $(0.03), missing the analyst consensus of $(0.01) by an 'Infinity percent' (indicating a larger loss than anticipated), and sales of …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.